We are live on ! Find out more
Bellevue Group

Bellevue Group Portfolio holdings

AUM $4.82B Turnover 23.39%
1-Year Est. Return 53.85%
 

Bellevue Group is a Swiss asset manager that focuses on healthcare investing, small and mid-cap companies and other growth strategies. Martin Bisang and four other founders started it in 1993, and through its subsidiary Bank am Bellevue it first became a major name in brokerage and block trading on the Swiss market. It sold that bank to Luxembourg's KBL Group in 2019, dropping its private client business and becoming a pure asset manager. In 2016 it bought the German asset manager StarCapital to build its presence in Germany, and in 2023 it launched Bellevue Obesity Solutions, a global equity fund.

This Fund
S&P 500
This Quarter Est. Return
+4.43%
1 Year Est. Return
+53.85%
3 Year Est. Return
+187.03%
5 Year Est. Return
+202.92%
10 Year Est. Return
+987.38%
AUM
$956M
AUM Growth
+$110M
Cap. Flow
+$88M
Cap. Flow %
9.21%
Top 10 Hldgs %
34.18%
Holding
136
New
4
Increased
63
Reduced
26
Closed
5
Avg Time Held
1.2 years
Top 10 Avg Time Held
0.8 years
Top 20 Avg Time Held
0.9 years

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$10.5M
2
ALGN icon
Align Technology
ALGN
+$9.7M
3
CELG
Celgene
CELG
+$9.6M
4
ELV icon
Elevance Health
ELV
+$9.1M
5
COR icon
Cencora
COR
+$7.21M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$7.35M
2
CI icon
Cigna
CI
+$4.96M
3
BCR
CR Bard
BCR
+$4.65M
4
CNC icon
Centene
CNC
+$4.38M
5
ALKS icon
Alkermes
ALKS
+$4.36M

Sector Composition

Rank Sector Weight
1 Healthcare 98.4%
2 Financials 0.94%
3 Industrials 0.35%
4 Miscellaneous 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
CELG
1
DELISTED
Celgene
CELG
$48.5M 5.07%
332,369
+70,377
+27% +$9.6M
2016 Q1
6 quarters
AMGN icon
2
Amgen
AMGN
$240B
$37M 3.87%
198,645
+34,917
+21% +$6.19M
2016 Q1
6 quarters
ALGN icon
3
Align Technology
ALGN
$11.5B
$35.9M 3.75%
192,746
+56,546
+42% +$9.7M
2017 Q1
2 quarters
GILD icon
4
Gilead Sciences
GILD
$210B
$32.6M 3.41%
402,541
+90,738
+29% +$6.94M
2016 Q1
6 quarters
ILMN icon
5
Illumina
ILMN
$30.6B
$32.6M 3.41%
168,104
+56,602
+51% +$10.5M
2016 Q1
6 quarters
ELV icon
6
Elevance Health
ELV
$93.8B
$32.5M 3.4%
171,143
+47,796
+39% +$9.1M
2016 Q1
6 quarters
ISRG icon
7
Intuitive Surgical
ISRG
$146B
$31.8M 3.32%
273,393
+60,039
+28% +$6.54M
2016 Q1
6 quarters
ABT icon
8
Abbott
ABT
$181B
$26.8M 2.81%
503,000
+60,000
+14% +$3.01M
2016 Q1
6 quarters
UNH icon
9
UnitedHealth
UNH
$314B
$26.7M 2.79%
136,270
+7,230
+6% +$1.4M
2016 Q1
6 quarters
EW icon
10
Edwards Lifesciences
EW
$60.6B
$22.5M 2.35%
617,580
+47,880
+8% +$1.83M
2016 Q1
6 quarters
LLY icon
11
Eli Lilly
LLY
$1.23T
$20.6M 2.16%
241,262
+60,189
+33% +$4.94M
2016 Q1
6 quarters
BSX icon
12
Boston Scientific
BSX
$63.3B
$20.3M 2.12%
696,000
+68,000
+11% +$1.88M
2016 Q1
6 quarters
WBA icon
13
DELISTED
Walgreens Boots Alliance
WBA
$20.2M 2.12%
262,060
+76,188
+41% +$6.11M
2017 Q1
2 quarters
BIIB icon
14
Biogen
BIIB
$37.1B
$18.4M 1.93%
58,900
-2,600
-4% -$770K
2016 Q1
6 quarters
INCY icon
15
Incyte
INCY
$24.3B
$17.1M 1.79%
146,366
+22,954
+19% +$2.9M
2016 Q1
6 quarters
MDT icon
16
Medtronic
MDT
$129B
$16.9M 1.77%
217,000
-88,500
-29% -$7.35M
2016 Q1
6 quarters
JAZZ icon
17
Jazz Pharmaceuticals
JAZZ
$15.9B
$16.9M 1.76%
115,252
+15,049
+15% +$2.28M
2016 Q1
6 quarters
COR icon
18
Cencora
COR
$66.9B
$16.4M 1.71%
197,991
+84,933
+75% +$7.21M
2017 Q1
2 quarters
ABMD
19
DELISTED
Abiomed Inc
ABMD
$14.4M 1.5%
85,110
+1,140
+1% +$172K
2016 Q2
5 quarters
WMGI
20
DELISTED
Wright Medical Group
WMGI
$14M 1.47%
541,801
+205,746
+61% +$5.67M
2016 Q1
6 quarters
DHR icon
21
Danaher
DHR
$161B
$13.6M 1.42%
179,126
+17,822
+11% +$1.32M
2016 Q4
3 quarters
BAX icon
22
Baxter International
BAX
$13.3B
$13.6M 1.42%
216,000
+10,000
+5% +$618K
2016 Q1
6 quarters
REGN icon
23
Regeneron Pharmaceuticals
REGN
$97.8B
$13.5M 1.41%
30,200
+2,100
+7% +$999K
2016 Q1
6 quarters
IONS icon
24
Ionis Pharmaceuticals
IONS
$4.56B
$13.5M 1.41%
265,706
+41,144
+18% +$2.16M
2016 Q1
6 quarters
HOLX icon
25
DELISTED
Hologic
HOLX
$13.3M 1.39%
363,101
+89,678
+33% +$3.62M
2016 Q1
6 quarters

Similar funds

Bellevue Group's Q3 2017 Portfolio in Review

As of Q3 2017, Bellevue Group held 136 positions worth $956M, up 13% from $846M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Bellevue Group deployed $88M of net new capital in Q3 2017, opening 4 new positions and adding to 63 existing holdings. Its largest new stake was Henry Schein: 48,450 shares worth $3.12M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Medtronic, an estimated $7.35M trimmed.

  • Bellevue Group's largest Q3 2017 buy was Henry Schein: 48,450 shares worth $3.12M.
  • Bellevue Group added most to Illumina in Q3 2017, an estimated $10.5M increase.
  • Bellevue Group's biggest Q3 2017 reduction was Medtronic, cutting an estimated $7.35M.
  • Bellevue Group fully exited China Biologic Products Holdings in Q3 2017, selling an estimated $4.1M.
  • Bellevue Group's ten largest holdings make up 34% of its $956M portfolio in Q3 2017.
  • Bellevue Group opened 4 new positions and closed 5 in Q3 2017.
  • Bellevue Group's portfolio value rose 13% quarter-over-quarter to $956M.

Based on Bellevue Group's 13F filing for Q3 2017, filed 13 Nov 2017.